STAT Plus: As efficacy of Constellation’s blood cancer drug wanes, the debate over its future ratchets higher
The response rate to an experimental myelofibrosis drug is falling, Constellation Pharmaceuticals, the drug’s maker, said Friday. But whether that’s good or bad news depends on your point of view.
With 30 myelofibrosis patients now treated and evaluable in its mid-stage study, the 24-week spleen response rate to CPI-0610 — when used on top of Incyte’s market-leading drug Jakafi — stands at 63%. The new data were presented Friday at the annual meeting of the European Hematology Association.
Continue to STAT Plus to read the full story…
